Cervical cancer screening—moving from the value of evidence to the evidence of value
Ce dossier présente la mise à jour des recommandations 2012 de l'"US Preventive Services Task Force" concernant les stratégies de dépistage du cancer du col de l'utérus
Widespread implementation of cytology-based screening programs has resulted in marked declines in cervical cancer incidence and mortality in the United States. Nonetheless, an estimated 13 240 women will be diagnosed with cervical cancer in 2018, and 4170 will die from the disease.1 It is likely that a sizable proportion of these women will not have been appropriately screened.2
JAMA Internal Medicine , éditorial en libre accès, 2017